Compare Bajaj Finserv Healthcare Fund vs UTI Healthcare Fund
Risk | Very High | Very High |
Rating | - | 4.0 |
Min SIP Amount | ₹500 | ₹500 |
Expense Ratio | 2.37 | 2.28 |
NAV | ₹9.59 | ₹269.31 |
Fund Started | 06 Dec 2024 | 01 Aug 2005 |
Fund Size | ₹338.55 Cr | ₹1101.63 Cr |
Exit Load | 1% for redemption within 3 Months | Exit load of 1% if redeemed within 30 days. |
Risk
Very High
Very High
Rating
-
4.0
Min SIP Amount
₹500
₹500
Expense Ratio
2.37
2.28
NAV
₹9.59
₹269.31
Fund Started
06 Dec 2024
01 Aug 2005
Fund Size
₹338.55 Cr
₹1101.63 Cr
Exit Load
1% for redemption within 3 Months
Exit load of 1% if redeemed within 30 days.
1 Year | - | -3.53% |
3 Year | - | 22.40% |
5 Year | - | 13.59% |
1 Year
-
-3.53%
3 Year
-
22.40%
5 Year
-
13.59%
Equity | 95.25% | 99.40% |
Cash | 0.41% | 0.59% |
Equity
95.25%
99.40%
Cash
0.41%
0.59%
Top 10 Holdings |
|
|
Top 10 Holdings
Divi's Laboratories Ltd. | 8.41% |
Sun Pharmaceutical Industries Ltd. | 8.24% |
Apollo Hospitals Enterprise Ltd. | 5.93% |
Aurobindo Pharma Ltd. | 5.54% |
Cipla Ltd. | 5.06% |
Piramal Pharma Ltd. | 4.40% |
Neuland Laboratories Ltd. | 4.26% |
Biocon Ltd. | 4.00% |
Emcure Pharmaceuticals Ltd. | 3.43% |
Fortis Healthcare Ltd. | 3.26% |
Sun Pharmaceutical Industries Ltd. | 9.37% |
Ajanta Pharma Ltd. | 7.16% |
Lupin Ltd. | 5.65% |
Glenmark Pharmaceuticals Ltd. | 4.06% |
Gland Pharma Ltd. | 3.60% |
Procter & Gamble Health Ltd. | 3.46% |
Dr. Reddy's Laboratories Ltd. | 3.46% |
Cipla Ltd. | 3.43% |
Alkem Laboratories Ltd. | 3.40% |
Apollo Hospitals Enterprise Ltd. | 3.39% |
Name | Sorbh Gupta | - |
Start Date | 10 Nov 2025 | - |
Name
Sorbh Gupta
-
Start Date
10 Nov 2025
-
Description | The Scheme seeks to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies. | The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. |
Launch Date | 06 Dec 2024 | 01 Aug 2005 |
Description
The Scheme seeks to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.
Launch Date
06 Dec 2024
01 Aug 2005